Ventavis® Registry Protocol

• Status: Terminated
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion
• Treatments: Iloprost

Criteria

Inclusion Criteria:

1. Have a current diagnosis of WHO Group I PAH

2. Have initiated therapy with commercial Ventavis® administered via portable nebulizer at least 3 months prior to study enrollment, either with commercial product or from participation in Actelion's Clinical Study AC-063A302

3. Age > or = 18 years old at the time of enrollment

Exclusion Criteria:

1. Meet the criteria for inclusion into WHO Groups II, III, IV or V PAH

2. Are not currently on commercial Ventavis®

3. Have initiated therapy with commercial Ventavis® administered via portable nebulizer less than 3 months prior to study enrollment